Search

Charles Sawyers, MD, Director of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center and a Howard Hughes Medical Institute investigator, has been named a "Dream Team" leader by Stand Up To Cancer and will co-lead a collaborative team that will receive $15 million to study targeted therapies to treat women's cancers.

… Wednesday, May 27, 2009 Charles Sawyers , MD, Director of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center (MSKCC) and a Howard Hughes Medical Institute investigator, has been named a “Dream Team” leader by Stand Up To Cancer and will co-lead a collaborative team

Despite the recent development of novel hormonal therapies - such as enzalutamide and abiraterone - directed at the androgen receptor in the management of castration-resistant prostate cancer, a proportion of men have disease that progresses on these drugs.

… Monday, June 5, 2017 Despite the recent development of novel hormonal therapies - such as enzalutamide and abiraterone - directed at the androgen receptor in the management of castration-resistant prostate cancer, a proportion of men have disease that progresses on these drugs. In this video Dr. Howard

In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study will also be published in a corresponding issue of JAMA Oncology.

… Monday, June 5, 2017 In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual

This research is important for developing better drugs and screening methods for pancreatic tumors.

… Monday, September 3, 2018 Summary Understanding how pancreatic cancer develops is important for developing better drugs and screening methods. Researchers are finding new clues by studying abnormal pancreas cells that sometimes turn into cancer. One universal truth about cancer is that the later it’s

MSK investigators find that the presence of certain gene mutations in patients’ blood may mean they are more likely to get a secondary leukemia.

… Thursday, August 10, 2017 Summary MSK investigators have found that the presence of certain gene mutations in patients’ blood may mean they are more likely to get a secondary leukemia. The discovery may lead to new methods for determining who is at greatest risk. One of the most devastating things that

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Thursday, May 7, 2020 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Tsvi Gal Is Named MSK’s Head of Infrastructure Tsvi Gal Tsvi Gal Tsvi Gal has been appointed Head of Infrastructure of MSK. Mr. Gal assumed his role on April 28. Mr. Gal will lead the hospital

Men with advanced prostate cancer treated with radical prostatectomy and adjuvant radiotherapy have a lower risk of cancer-specific death and improved overall survival compared to men treated with radiotherapy plus androgen deprivation therapy.

… Thursday, November 8, 2018 Men with advanced prostate cancer treated with radical prostatectomy and adjuvant radiotherapy have a lower risk of cancer-specific death and improved overall survival compared to men treated with radiotherapy plus androgen deprivation therapy, according to our recent observational

Drs. Anna-Katerina Hadjantonakis and Robert Farese were elected to the 2026 class of the American Academy of Arts and Sciences.

… Thursday, April 23, 2026 Two Memorial Sloan Kettering Cancer Center (MSK) researchers were elected to the 2026 class of the American Academy of Arts and Sciences. Developmental biologist Anna-Katerina Hadjantonakis, PhD , and physician-scientist Robert Farese, Jr., MD , were among the 252 leaders in

Local control rates and overall survival (OS) were significantly higher for patients with brain metastases treated with adjuvant stereotactic radiosurgery (SRS) within two months of resection, compared to longer time intervals, according to our new study published recently in Neuro-Oncology Practice.

… Thursday, September 23, 2021 Local control rates and overall survival (OS) were significantly higher for patients with brain metastases treated with adjuvant stereotactic radiosurgery (SRS) within two months of resection, compared to longer time intervals, according to our new study published recently

A landmark study led in part by physician-researchers from Memorial Sloan Kettering is giving new hope to some people with metastatic colorectal cancer.

… Wednesday, December 23, 2020 A landmark study led in part by physician-researchers from Memorial Sloan Kettering is giving new hope to some people with metastatic colorectal cancer. In a recent issue of the  New England Journal of Medicine , results from the phase III study — Keynote 177 — provided further